Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion

Core Insights - Kura Oncology, Inc. is highlighted as one of the 20 best biotech stocks under $20 to buy now [1] - Leerink Partners has revised the price target for Kura Oncology to $20 from $25 while maintaining an Outperform rating, reflecting updates based on preliminary Q4 financial results [2] - Kura Oncology reported that its product KOMZIFTI generated $2.1 million in net sales during its first five weeks of commercial availability [3] - The company has outlined anticipated milestones for 2026, including expanding the use of ziftomenib and progressing current AML clinical investigations [4] - Kura Oncology is focused on developing targeted therapies for cancer and hematologic malignancies, with a pipeline of precision small-molecule inhibitors [5]